Out of Specification frameworks may overestimate clinical risk: a lesson from commercial CAR-T products deviations

This publication has 108 references indexed in Scilit:

• In vivo generation of CAR T cells: biology, delivery platforms, clinical promise, and translational challenges
  Blood Immunology & Cellular Therapy, 2025
• Lymphocyte Kinetics and Outcomes of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma With Out of Specification Products
  American Journal of Hematology, 2025
• Low platelet counts and low CD4/CD8 ratios at apheresis increase the risk of CAR T-cell manufacturing failure in myeloma
  Blood Neoplasia, 2024
• Lymphocyte recovery after bendamustine therapy in patients with mantle cell lymphoma. Results of a retrospective analysis and prognostic impact in the CAR-T era
  Annals of Hematology, 2024
• Chimeric antigen receptor‐T cell therapy shows similar efficacy and toxicity in patients with diffuse large B‐cell lymphoma aged 70 and older compared to younger patients: A multicenter cohort study
  HemaSphere, 2024
• Optimizing the CAR T-Cell Therapy Experience in Multiple Myeloma: Clinical Pearls From an Expert Roundtable
  Clinical Lymphoma Myeloma and Leukemia, 2024
• Real‐world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B‐cell lymphoma
  Cancer Medicine, 2021
• Manufacture of Chimeric Antigen Receptor T Cells from Mobilized Cyropreserved Peripheral Blood Stem Cell Units Depends on Monocyte Depletion
  Transplantation and Cellular Therapy, 2019
• The impact of leukapheresis on immune-cell number and function in patients with advanced cancer
  Cancer Immunology, Immunotherapy, 2015
• T cell subset-specific susceptibility to aging
  Clinical Immunology, 2008